Allucent’s client requested support to bring an AAV gene therapy for a rare neurodegenerative disease into the clinic for a Phase 1b study in patients. Dosescaling from pharmacology and toxicology studies by brain volume alone for administration directly into the brain by MRI-Guided Convection-EnhancedDelivery led to human equivalent doses that lacked a margin of safety.
Download the full case study below to learn more.